modeling and simulation to select oncology dosages - session 3
Published 4 months ago • 805 plays • Length 2:31:56Download video MP4
Download video MP3
Similar videos
-
5:03:04
modeling and simulation to evaluate intrinsic and extrinsic factors
-
24:19
panel on emerging use of modeling and simulation for bioequivalence
-
19:09
regional deposition and systemic pharmacokinetic data of oindps with modeling and simulation
-
5:22
using modeling and simulation with fda
-
3:48
fda oncology center of excellence’s project facilitate
-
48:50
getting the best dose: the clinical pharmacology studies that help achieve this goal
-
1:05:36
project optimus – fda’s new dose optimization & selection paradigm in oncology drug development
-
15:50
oncology center of excellence introduction and overview of the oncology therapy development workshop
-
29:20
fda oncology drug development overview – past to present
-
18:28
model informed drug development approaches for immunogenicity assessments workshop
-
0:16
doctor vs. nurse: education #shorts
-
5:58
fda d.i.s.c.o.: niraparib in ovarian cancer transcript
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
58:45
best practices in clinical pharmacology gap analysis
-
52:38
simulations and the fda
-
16:24
pbpk modeling and simulation used in assessing be for generic ophthalmic products (19of39)
-
1:59:15
2021 fda science forum – session #4 - product development and manufacturing
-
14:29
special sessions: "regulatory insights to the 2021 early stage breast cancer approvals"
-
17:32
model informed drug development approaches for immunogenicity assessments workshop